Insider · CIK 0001708172

KASINGER JAMES R.

Reports to the SEC for 1 company · BOSTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001708172

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-14	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−1,040 sh	$49.26	−$51.2K	95,857
2026-10-13	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+2,113 sh	—	—	96,897
2026-10-13	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−2,113 sh	—	—	0
2026-10-06	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+1,990 sh	$13.62	+$27.1K	96,774
2026-10-06	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−1,990 sh	$60.04	−$119K	94,784
2026-10-06	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−1,990 sh	—	—	81,242
2026-09-22	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+10.4K sh	$13.62	+$142K	105,184
2026-09-22	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−10.4K sh	$60.24	−$626K	94,784
2026-09-22	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)M Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−10.4K sh	—	—	83,232
2026-05-29	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	General Counsel and Secretary	AAward	+17K sh	—	—	17,000
2026-03-23	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−3,182 sh	$46.78	−$149K	94,308
2026-03-20	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+6,250 sh	—	—	97,490
2026-03-20	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	General Counsel and Secretary	AAward	+38.5K sh	—	—	38,499
2026-03-20	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	General Counsel and Secretary	AAward	+25K sh	—	—	25,000
2026-03-20	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−6,250 sh	—	—	12,000
2026-03-16	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−3,450 sh	$48.26	−$166K	91,240
2026-03-14	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+6,875 sh	—	—	94,690
2026-03-14	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−6,875 sh	—	—	20,625
2026-03-11	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−2,800 sh	$52.80	−$148K	87,815
2026-03-10	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+5,500 sh	—	—	90,615
2026-03-10	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−5,500 sh	—	—	5,500
2026-02-19	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−2,112 sh	$52.58	−$111K	85,115
2026-02-18	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+3,825 sh	—	—	87,227
2026-02-18	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−3,825 sh	—	—	0
2025-10-14	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−1,076 sh	$66.60	−$71.7K	83,402
2025-10-13	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+2,114 sh	—	—	84,478
2025-10-13	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−2,114 sh	—	—	2,113
2025-10-03	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	General Counsel and Secretary	AAward	+16.5K sh	—	—	16,500
2025-03-21	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−3,185 sh	$41.23	−$131K	81,729
2025-03-20	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+6,250 sh	—	—	84,914
2025-03-20	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−6,250 sh	—	—	18,750
2025-03-14	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	General Counsel and Secretary	AAward	+36.7K sh	—	—	36,666
2025-03-14	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	General Counsel and Secretary	AAward	+27.5K sh	—	—	27,500
2025-03-12	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−1,116 sh	$43.32	−$48.3K	78,664
2025-03-11	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−2,850 sh	$42.42	−$121K	77,530
2025-03-11	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+2,250 sh	—	—	79,780
2025-03-11	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−2,250 sh	—	—	0
2025-03-10	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+5,500 sh	—	—	80,380
2025-03-10	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−5,500 sh	—	—	11,000
2025-02-19	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−1,947 sh	$52.80	−$103K	74,880
2025-02-18	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−9,595 sh	$53.85	−$517K	73,002
2025-02-18	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+3,825 sh	—	—	76,827
2025-02-18	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−3,825 sh	—	—	3,825
2025-02-16	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+20K sh	—	—	82,597
2025-02-16	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−20K sh	—	—	0
2024-10-16	CRSPCRISPR Therapeutics AG · Stock Option (Right to Buy)A Award	General Counsel and Secretary	AAward	+18.3K sh	—	—	18,333
2024-10-16	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsA Award	General Counsel and Secretary	AAward	+30K sh	—	—	30,000
2024-10-14	CRSPCRISPR Therapeutics AGS Sale	General Counsel and Secretary	SSale	−1,089 sh	$46.28	−$50.4K	62,597
2024-10-13	CRSPCRISPR Therapeutics AGM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	+2,113 sh	—	—	63,686
2024-10-13	CRSPCRISPR Therapeutics AG · Restricted Stock UnitsM Exercise/Conversion	General Counsel and Secretary	MExercise/Conversion	−2,113 sh	—	—	4,227

Recent filings

Accepted (ET)
Oct 154
KASINGER JAMES R.0001193125-26-423057
SEC(opens sec.gov)
Oct 84
KASINGER JAMES R.0001193125-26-418101
SEC(opens sec.gov)
Sep 244
KASINGER JAMES R.0001193125-26-401237
SEC(opens sec.gov)
Jun 24
KASINGER JAMES R.0001193125-26-253929
SEC(opens sec.gov)
Mar 244
KASINGER JAMES R.0001193125-26-122274
SEC(opens sec.gov)
Mar 174
KASINGER JAMES R.0001193125-26-111281
SEC(opens sec.gov)
Mar 124
KASINGER JAMES R.0001193125-26-104481
SEC(opens sec.gov)

Companies

CRISPR Therapeutics AGGeneral Counsel and SecretaryCRSP

Address

C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET

BOSTON, MA, 02127